What is Abogen?
Founded in 2012, Abogen is dedicated to advancing personalized medicine through the development of novel alternatives to traditional blood draws for comprehensive genomic information. This innovative approach aims to streamline and enhance the accessibility of genomic data, paving the way for more tailored and effective medical treatments. The company's focus on developing groundbreaking technologies positions it at the forefront of the rapidly evolving biotech landscape, addressing critical needs in diagnostics and therapeutic development.
How much funding has Abogen raised?
Abogen has raised a total of $1.1B across 3 funding rounds:
Multiple Rounds
$1.1B
Series B (2021): $92M with participation from Highlight Capital, YF Capital, Ming Bioventures, TF Capital, SDIC Venture Capital, Qiming Venture Partners, LYFE Capital, GL Ventures, and PICC Capital Investment Management
Series C (2021): $700M led by Invesco Developing Markets Fund and Temasek
Unspecified (2021): $300M supported by 5Y Capital, Chimera Abu Dhabi, SoftBank Group, Mirae Asset Financial, and Fortune Ocean
Key Investors in Abogen
5Y Capital
5Y Capital, formerly known as 晨兴资本, is a venture capital firm that believes in the transformative power of entrepreneurship. They focus on identifying and nurturing exceptional entrepreneurs who possess unique talents, often overlooked by others. The firm is dedicated to fostering a spirit of pride and ambition among its team and portfolio companies, aiming to contribute to meaningful advancements in the world. With offices in Shanghai, Beijing, Shenzhen, and Hong Kong, 5Y Capital actively supports a diverse range of innovative businesses.
SoftBank Group
SoftBank Group Corp. is a global technology holding company driving innovation across telecommunications, internet services, artificial intelligence, smart robotics, IoT, and clean energy technologies. Through its diverse portfolio of companies and strategic investments, including leading semiconductor IP providers, SoftBank Group supports the development and scaling of transformative technologies worldwide. The company leverages its global investment platforms, including the SoftBank Vision Fund, to identify and back businesses that have the potential to shape the next phase of the Information Revolution. With a focus on long-term growth, technological advancement, and industry leadership, SoftBank Group combines strategic capital, operational expertise, and a forward-looking vision to foster innovation and create lasting value across its global network of companies.
Qiming Venture Partners
启明创投 is a prominent venture capital firm that focuses on investing in innovative companies across various sectors, including technology, healthcare, and artificial intelligence. They aim to support entrepreneurs by providing industry resources, strategic guidance, and fostering strong relationships with stakeholders. The firm has a notable track record of backing successful startups, helping them achieve significant growth and market presence. With a commitment to creating long-term value for society, 启明创投 actively engages in financing, IPOs, and mergers and acquisitions.
What's next for Abogen?
With its recent major strategic investment, Abogen is poised to accelerate its research and development initiatives, further refine its proprietary technologies, and potentially expand its market reach. The substantial capital infusion suggests a strategic focus on scaling operations, advancing clinical trials, and solidifying its position as a leader in personalized medicine. This funding will likely enable Abogen to pursue key milestones, foster strategic partnerships, and drive innovation in genomic information acquisition and application, ultimately contributing to the future of healthcare.
See full Abogen company page
